摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl 5-[(diallylamino)methyl]-2-(1,4-dioxa-8-azaspiro[4,5]dec-8-ylsulfonyl)thiophene-3-carboxylate | 406486-97-3

中文名称
——
中文别名
——
英文名称
ethyl 5-[(diallylamino)methyl]-2-(1,4-dioxa-8-azaspiro[4,5]dec-8-ylsulfonyl)thiophene-3-carboxylate
英文别名
Ethyl 5-[[bis(prop-2-enyl)amino]methyl]-2-(1,4-dioxa-8-azaspiro[4.5]decan-8-ylsulfonyl)thiophene-3-carboxylate
ethyl 5-[(diallylamino)methyl]-2-(1,4-dioxa-8-azaspiro[4,5]dec-8-ylsulfonyl)thiophene-3-carboxylate化学式
CAS
406486-97-3
化学式
C21H30N2O6S2
mdl
——
分子量
470.611
InChiKey
FMUVGJZOMSJMIM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    31
  • 可旋转键数:
    11
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.57
  • 拓扑面积:
    122
  • 氢给体数:
    0
  • 氢受体数:
    9

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    ethyl 5-[(diallylamino)methyl]-2-(1,4-dioxa-8-azaspiro[4,5]dec-8-ylsulfonyl)thiophene-3-carboxylate间甲氧基苯甲酰氯四(三苯基膦)钯 三乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 2.5h, 以61%的产率得到ethyl 2-(1,4-dioxa-8-azaspiro[4,5]dec-8-ylsulfonyl)-5-{[(3-methoxybenzoyl)amino]methyl}thiophene-3-carboxylate
    参考文献:
    名称:
    Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases
    摘要:
    本发明涉及具有亲脂基团并在生理条件下基本可溶的磺胺基衍生物。所述化合物特别适用作药用活性化合物。本发明还涉及含有这种磺胺基衍生物的药物配方。所述磺胺基衍生物是JNK途径的高效调节剂,特别是JNK 2和3的高效和选择性抑制剂。本发明还涉及新型磺胺基衍生物以及它们的制备方法。 根据本发明的式I化合物适用于药用剂的那些化合物是这样的: Ar1和Ar2分别独立地是取代或未取代的芳基或杂环芳基, X是O或S,优选为O; R1是氢或C1-C6烷基,或R1与Ar1形成取代或未取代的5-6元饱和或不饱和环; n是0到5的整数,优选为1-3之间,最优选为1; 式I中的Y是未取代或取代的4-12元饱和环或双环烷基,其上取代有至少一个可离子化基团,该基团连接有一个亲脂链,并且含有至少一个氮原子,其中所述环中的一个氮原子与式I的磺酰基形成键合,从而提供磺胺基。
    公开号:
    EP1193268A1
  • 作为产物:
    描述:
    N,N-diallyl-N-{[5-(1,4-dioxa-8-azaspiro[4,5]dec-8-ylsulfonyl)thien-2-yl]methyl}amine氯甲酸乙酯叔丁基锂 作用下, 以 四氢呋喃正己烷 为溶剂, 反应 0.08h, 以37%的产率得到ethyl 5-[(diallylamino)methyl]-2-(1,4-dioxa-8-azaspiro[4,5]dec-8-ylsulfonyl)thiophene-3-carboxylate
    参考文献:
    名称:
    Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein JunKinases
    摘要:
    本发明涉及具有基本亲水性磺胺基衍生物或具有基本亲水性基团的磺胺基衍生物,其化学式为I,特别用作药用活性化合物,以及含有这种磺胺基衍生物的药物配方。所述磺胺基衍生物是JNK途径的高效调节剂,特别是JNK 2和3的高效选择性抑制剂。本发明还涉及新型磺胺基衍生物以及其制备方法。 根据本发明的化学式I的化合物适用于药用剂的那些是: Ar1是取代或未取代的芳基或杂芳基; Ar2是携带至少一个亲水取代基的芳基或杂芳基; X是O或S,优选O; R1是氢或C1-C6烷基,或R1与Ar1形成取代或未取代的5-6元饱和或不饱和环; n是0到5之间的整数,优选在1-3之间,最优选1; 化学式I中的Y是未取代或取代的含有至少一个氮原子的4-12元饱和环或双环烷基,其中所述环中的一个氮原子与化学式I的磺酰基形成键合,从而提供磺胺基。
    公开号:
    EP1193267A1
点击查看最新优质反应信息

文献信息

  • Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein junkinases
    申请人:——
    公开号:US20040077632A1
    公开(公告)日:2004-04-22
    The present invention is related to substantially hydrophilic sulfonamide derivatives, or sulfonamide derivatives having a substantially hydrophilic moiety, of formula I notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such sulfonamide derivatives. Said sulfonamide derivatives are efficient modulators of the JNK pathway, they are in particular efficient and selective inhibitors of JNK 3. The present invention is furthermore related to novel sulfonamide derivatives as well as to methods of their preparation. 1 The compounds of formula I according to the present invention being suitable pharmaceutical agents are those wherein Ar 1 is a substituted or unsubstituted aryl or heteroaryl; Ar 2 is an aryl or heteroaryl group carrying at least one hydrophilic substituent; X is O or S, preferably O; R 1 is hydrogen or a C 1 -C 6 -alkyl group, or R 1 forms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with Ar 1 ; n is an integer from 0 to 5, preferably between 1-3 and most preferred 1; Y within formula I is an unsubstituted or a substituted 4-12-membered saturated cyclic or bicyclic alkyl containing at least one nitrogen atom, whereby one nitrogen atom within said ring is forming a bond with the sulfonyl group of formula I thus providing a sulfonamide.
    本发明涉及具有基本亲性磺酰胺衍生物或具有基本亲性基团的磺酰胺衍生物的公式I,特别是作为药物活性化合物的使用,以及包含这些磺酰胺衍生物的制药配方。所述磺酰胺衍生物是JNK途径的有效调节剂,特别是JNK 3的有效和选择性抑制剂。本发明还涉及新的磺酰胺衍生物及其制备方法。根据本发明适合作为药物剂的公式I化合物是其中Ar1是取代或未取代的芳基或杂芳基;Ar2是携带至少一个亲性取代基的芳基或杂芳基;X是O或S,优选为O;R1是氢或C1-C6烷基,或R1与Ar1形成取代或未取代的5-6成员饱和或不饱和环;n是0到5的整数,优选为1-3,最优选为1;公式I中的Y是未取代或取代的4-12成员饱和环或双环烷基,其中至少有一个氮原子,该氮原子在所述环中与公式I的磺酰基形成键,从而提供磺酰胺。
  • Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moietties as inhibitors of protein junkinases
    申请人:——
    公开号:US20040077854A1
    公开(公告)日:2004-04-22
    The present invention is related to sulfonamide derivatives having a lipophilic moiety and which are substantially soluble. Said compounds are notably for use as pharmaceutically active compounds. The present invention also related to pharmaceutical formulations containing such sulfonamide derivatives. Said sulfonamide derivatives are efficient modulators of the JNK pathway, they are in particular efficient and selective inhibitors of JNK 2 and 3. The present invention is furthermore related to novel sulfonamide derivatives as well as to methods of their preparation. The compounds of formula (I) according to the present invention being suitable pharmaceutical agents are those wherein Ar1 and Ar2 are independently from each other substituted or unsubstituted aryl or heteroaryl groups, X is O or S, preferably O;R1 is hydrogen or a C1-C6-alkyl group, or R1 forms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with Ar1;n is an integer from 0 to 5, preferably between 1-3 and most preferred 1;Y within formula (I) is an unsubstituted or a substituted 4-12-membered saturated cyclic or bicyclic alkyl which is substituted with at least one ionisable moiety to which a lipophilic chain is attached and which is containing at least one nitrogen atom, whereby one nitrogen atom within said ring is forming a bond with the sulfonyl group of formula (I) thus providing a sulfonamide.
    本发明涉及具有亲脂基团且基本溶解的磺酰胺衍生物,该化合物特别适用于作为药物活性化合物。本发明还涉及含有这种磺酰胺衍生物的药物制剂。该磺酰胺衍生物是JNK途径的有效调节剂,尤其是JNK2和3的有效和选择性抑制剂。本发明还涉及新的磺酰胺衍生物以及它们的制备方法。本发明所述的公式(I)化合物适用于药物制剂,其中Ar1和Ar2分别是取代或未取代的芳基或杂环芳基基团,X为O或S,优选为O;R1为氢或C1-C6烷基,或R1与Ar1形成取代或未取代的5-6元饱和或不饱和环;n为0到5的整数,优选为1-3,最优选为1;公式(I)中的Y是未取代或取代的4-12元饱和环或双环烷基,其被至少一个离子化基团取代,并连接有一个亲脂链,并且含有至少一个氮原子,其中该环中的一个氮原子与公式(I)中的磺酰基形成键合,从而提供磺酰胺。
  • Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of Protein Jun-kinases
    申请人:Merck Serono SA
    公开号:EP1322642B1
    公开(公告)日:2013-09-04
  • PHARMACEUTICALLY ACTIVE HYDROPHILIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF PROTEIN JUNKINASES
    申请人:Merck Serono SA
    公开号:EP1322641B1
    公开(公告)日:2012-07-25
  • US7544700B2
    申请人:——
    公开号:US7544700B2
    公开(公告)日:2009-06-09
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (双(2,2,2-三氯乙基)) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-氨氯地平-d4 (S)-8-氟苯并二氢吡喃-4-胺 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯 (R,S)-可替宁N-氧化物-甲基-d3 (R,S)-六氢-3H-1,2,3-苯并噻唑-2,2-二氧化物-3-羧酸叔丁酯 (R)-(+)-5'-苄氧基卡维地洛 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-卡洛芬 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (R)-4-异丙基-2-恶唑烷硫酮 (R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (N-{4-[(6-溴-2-氧代-1,3-苯并恶唑-3(2H)-基)磺酰基]苯基}乙酰胺) (E)-2-氰基-3-(5-(2-辛基-7-(4-(对甲苯基)-1,2,3,3a,4,8b-六氢环戊[b]吲哚-7-基)-2H-苯并[d][1,2,3]三唑-4-基)噻吩-2-基)丙烯酸 (E)-2-氰基-3-[5-(2,5-二氯苯基)呋喃-2-基]-N-喹啉-8-基丙-2-烯酰胺 (8α,9S)-(+)-9-氨基-七氢呋喃-6''-醇,值90% (6R,7R)-7-苯基乙酰胺基-3-[(Z)-2-(4-甲基噻唑-5-基)乙烯基]-3-头孢唑啉-4-羧酸二苯甲基酯 (6-羟基嘧啶-4-基)乙酸 (6,7-二甲氧基-4-(3,4,5-三甲氧基苯基)喹啉) (6,6-二甲基-3-(甲硫基)-1,6-二氢-1,2,4-三嗪-5(2H)-硫酮) (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5R,Z)-3-(羟基((1R,2S,6S,8aS)-1,3,6-三甲基-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-八氢萘-1-基)亚甲基)-5-(羟甲基)-1-甲基吡咯烷-2,4-二酮 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-(4-乙氧基-3-甲基苄基)-1,3-苯并二恶茂) (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氯-2,1,3-苯并噻二唑-4-基)-氨基甲氨基硫代甲酸甲酯一氢碘 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (5-氨基-1,3,4-噻二唑-2-基)甲醇 (4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] (4-(4-氯苯基)硫代)-10-甲基-7H-benzimidazo(2,1-A)奔驰(德)isoquinolin-7一 (4-苄基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (4-己基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4,5-二甲氧基-1,2,3,6-四氢哒嗪)